Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 16/20 | 0.53 |
| ▸ | KLK1 | P06870 | 3/20 | 0.53 |
| ▸ | FPR2 | P25090 | 2/20 | 0.43 |
| ▸ | KLKB1 | P03952 | 9/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17295685 | 0.96 | F11 (0.56) | F11KLK1FPR2KLKB1 | |
| SCHEMBL19874085 | 0.89 | F11 (0.45) | F11KLK1FPR2KLKB1NPC1 | |
| SCHEMBL30517942 | 0.85 | F11 (0.41) | F11KLK1FPR2KLKB1NPC1 | |
| SCHEMBL17295757 | 0.84 | F11 (0.46) | F11KLK1FPR2KLKB1NPC1 | |
| SCHEMBL19874161 | 0.84 | F11 (0.46) | F11KLK1KLKB1NPC1RAB9A | |
| SCHEMBL19874158 | 0.84 | F11 (0.46) | F11KLK1KLKB1NPC1RAB9A | |
| SCHEMBL19874311 | 0.84 | F11 (0.45) | F11KLK1FPR2KLKB1NPC1 | |
| SCHEMBL17295708 | 0.82 | RAB9A (0.51) | F11KLK1NPC1RAB9AKMT2A | |
| SCHEMBL19886605 | 0.81 | F11 (0.44) | F11KLK1FPR2KLKB1NPC1 | |
| SCHEMBL19886595 | 0.80 | ALDH1A1 (0.43) | FPR2NPC1RAB9AKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3500556-B1 | PYRIDINE-1-OXIDE DERIVATIVES AND THEIR USE AS FACTOR XIA INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3500556-A1 | PYRIDINE-1-OXIDE DERIVATIVES AND THEIR USE AS FACTOR XIA INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2019-06-26 | — | — | EP | disclosed |
| US-10143681-B2 | Factor XIa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-12-04 | — | — | US | disclosed |
| WO-2018039094-A1 | PYRIDINE-1-OXIDE DERIVATIVES AND THEIR USE AS FACTOR XIA INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-03-01 | — | — | WO | disclosed |
| US-20180050022-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP (US) | 2018-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10143681-B2 | Factor XIa inhibitors | F11, F2, TFPI | F11 1/4885KLK1 25/4885FPR2 1271/4885 |
| US-20180050022-A1 | FACTOR XIa INHIBITORS | F11, F2, TFPI | F11 1/4885KLK1 25/4885FPR2 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.